<DOC>
	<DOCNO>NCT00175266</DOCNO>
	<brief_summary>Islet transplantation investigate treatment Type 1 diabetes mellitus select patient inadequate glucose control despite insulin therapy . However , perennial hope approach would result long-term freedom need exogenous insulin , stabilization secondary complication diabetes , fail materialize practice . The goal present study therefore improve safety efficacy clinical islet-alone transplantation minimize dependence calcineurin-inhibitor therapy - thereby avoid potential nephrotoxicity , furthermore improve success single-donor islet infusion avoid diabetogenic immunosuppression . Campath-1H , combine Infliximab induction therapy provide unique opportunity minimize dosing maintenance long-term immunosuppression promote islet engraftment .</brief_summary>
	<brief_title>Islet Transplantation Using Campath-1H Infliximab Induction</brief_title>
	<detailed_description>This single-centre , prospective , open-label study Type 1 diabetic participant receive islet cell transplant ; participant receive Campath-1H + Infliximab induction therapy follow sirolimus ultra-low dose tacrolimus maintenance therapy . The primary objective protocol ass safety treatment regimen adult Type 1 diabetic participant receive first islet transplant .</detailed_description>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>must Type 1 diabetes mellitus 5 year diabetes must complicate least one follow situation persist despite intensive insulin management effort . The complicating situation ( 1 ) Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L ; ( 2 ) Metabolic lability/instability , characterize MAGE ≥ 11.0 mmol/L wide swing blood glucose despite optimal diabetes therapy ; ( 3 ) Despite effort optimal glucose control , progressive secondary complication diabetes , include retinopathy , neuropathy , nephropathy Severe coexist cardiac disease Active alcohol substance abuse Psychiatric disorder make subject suitable candidate transplantation Active infection include hepatitis C , hepatitis B , HIV , TB Any history current malignancy except squamous basal skin cancer BMI &gt; 28 kg/m2 body weight &gt; 85 kg screen visit Positive fast Cpeptide response assessment ( 2 positive result ) Creatinine clearance &lt; 80 mL/min/1.73 m2 Serum creatinine &gt; 150 µmol/L Macroalbuminuria ( urinary albumin excretion rate &gt; 300 mg/24h ) Baseline Hb &lt; 105g/L woman , &lt; 130 g/L men Baseline LFT 's outside normal range Untreated proliferative retinopathy Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breast feed Previous transplant , evidence sensitization PRA Insulin requirement &gt; 1.0 IU/kg/day HbA1C &gt; 0.12 Hyperlipidemia ( fast LDL cholesterol &gt; 3.4 mmol/L , treat untreated ; and/or fast triglyceride &gt; 2.3 mmol/L ) Under treatment medical condition require chronic use steroid Use coumadin anticoagulant therapy ( except aspirin ) subject PT INR &gt; 1.5 Untreated Addison 's disease Untreated Celiac disease Untreated thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>islet</keyword>
	<keyword>transplantation</keyword>
</DOC>